320
Views
6
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

The Relationship of Vogt–Koyanagi–Harada Syndrome to Ocular Hypertension and Glaucoma

, BA, , MD, , MD, , DrPH, , MD & , MD
Pages 748-752 | Received 26 Mar 2016, Accepted 10 May 2016, Published online: 20 Jul 2016

REFERENCES

  • Read RW, Rechodouni A, Butani Net al. Complications and prognostic factors in Vogt–Koyanagi–Harada disease. Am J Ophthalmol. 2001;131:599–606.
  • Read RW. Vogt–Koyanagi–Harada disease. Ophthalmol Clin N Am. 2002;15:333–341.
  • Rubsamen PE, Gass DM. Vogt–Koyanagi–Harada syndrome. Arch Ophthalmol. 1991;109:682–687.
  • Forster DJ, Rao NA, Hill RA, et al. Incidence and management of glaucoma in VKH syndrome. Ophthalmology. 1993;100:613–618.
  • Perry HD, Font R. Clinical and histopathologic observations in severe VKH. Am J Ophthalmol. 1977;83:242–254.
  • Kimura R, Suzuki A, Maekawa N. Four cases of secondary angle closure glaucoma caused by Harada’s disease. Jpn J Clin Ophthalmol. 1973;26:827–830.
  • Yang P, Liu X, Zhou H, et al. Vogt–Koyanagi–Harada disease presenting as acute angle closure glaucoma at onset. Clin Experiment Ophthalmol. 2011;39:639–647.
  • Rao NA, Gupta A, Dustin L, et al. Frequency of distinguishing clinical features in Vogt–Koyanagi–Harada disease. Ophthalmology. 2010;117:591–599.
  • Al-Kharashi AS, Aldibhi H, Al-Fraykh H, et al. Prognostic factors in Vogt–Koyanagi–Harada disease. Int Ophthalmol. 2007;27:201–210.
  • El‐Asrar A, Ahmed M, Al Tamimi M, et al. Prognostic factors for clinical outcomes in patients with Vogt–Koyanagi–Harada disease treated with high‐dose corticosteroids. Acta Ophthalmol. 2013;91:e486–e493.
  • Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 2006;113:1020–1027.
  • The Multicenter Uveitis Corticosteroid Treatment (MUST) Trial Follow-up Study Research Group. Quality of life and risks associated with systemic anti-inflammatory therapy versus fluocinolone acetonide intraocular implant for intermediate uveitis, posterior uveitis, or panuveitis: fifty-four-month results of the multicenter uveitis corticosteroid treatment trial and follow-up study. Ophthalmology. 2015;122:1976–1986.
  • Parekh A, Srivastava S, Bena J, et al. Risk factors associated with intraocular pressure increase in patients with uveitis treated with the fluocinolone acetonide implant. JAMA Ophthalmol. 2015;133:568–573.
  • Arevalo JF, Lasave AF, Gupta V, et al. Clinical outcomes of patients with Vogt–Koyanagi–Harada disease over 12 years at a tertiary center. Ocul Immunol Inflamm. 2015. doi: 10.3109/09273948.2015.1025984.
  • Siddique SS, Suelves AM, Baheti U, et al. Glaucoma and uveitis. Surv Ophthalmol. 2013;58:1–10.
  • Kanda T, Shibata M, Taguchi M, et al. Prevalence and aetiology of ocular hypertension in acute and chronic uveitis. Br J Ophthalmol. 2014;98:932–936.
  • Moorthy R, Mermoud A, Baerveldt G, et al. Glaucoma associated with uveitis. Surv Ophthalmol. 1996;41:361–394.
  • Muñoz-Negrete, FJ, Moreno-Montañés, et al. Current approach in the diagnosis and management of uveitic glaucoma. Biomed Res Int. 2015;2015:742792.
  • Kishi A, Nao-i N, Sawada A. Ultrasound biomicroscopic findings of acute angle-closure glaucoma in Vogt–Koyanagi–Harada syndrome. Am J Ophthalmol. 1996;122:735–737.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.